 | Up a level |
Journal Article
Ahmad, A. R., Tho, L. M., Chik, Y. K. J., Lee, W. C. K., Yang, T-Y., Le, X., Eisert, A. K., Himpe, U., De Bondt, C., Mazieres, J., Petrini, I., Lam, W-S., Joshi, K., Berghoff, K., Vlassak, S., Karachaliou, N., Van der Wekken, A. J. and Hsia, T-C. (2022). Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series. Ann. Oncol., 33. S. S1584 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Eisert, A. K., Scheffler, M., Michels, S., Schultheis, A., Koenig, K., Merkelbach-Bruse, S., Serke, M., Ko, Y., Gerigk, U., Geist, T., Heukamp, L. C., Buettner, R. and Wolf, J. (2014). GENETIC VARIABILITY AND CLINICAL PRESENTATION OF PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING MET-AMPLIFICATIONS. Ann. Oncol., 25. OXFORD: OXFORD UNIV PRESS. ISSN 1569-8041
Glaser, M., Von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Wompner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A. K., Fischer, R. N., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buttner, R., Wolf, J. and Scheffler, M. (2022). The biological effect of small-scale ROS1 aberrations: An in silico analysis. Ann. Oncol., 33 (7). S. S1327 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Kron, A., Scheffler, M., Ihle, M., Michels, S., Sueptitz, J., Prang, D., Jakobs, F., Nogova, L., Fischer, R. N., Eisert, A. K., Riedel, R., Kron, F., Hillmer, A., Loges, S., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2022). EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB). Ann. Oncol., 33 (7). S. S1006 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041
Marinello, A., Vasseur, D., Conci, N., Fallet, V., Audigier-Valette, C., Cousin, S., Tabbo, F., Guisier, F., Russo, A., Blanco, A. Calles, Metro, G., Massa, G., Citarella, F., Eisert, A. K., Gomez, P. Iranzo, Tagliamento, M., Mezquita, L., Lindsay, C., Ponce, S. and Aldea, M. (2022). Mechanisms of primary and secondary resistance to RET inhibitors in patients with RET-positive advanced NSCLC. Ann. Oncol., 33 (7). S. S1013 - 2. AMSTERDAM: ELSEVIER. ISSN 1569-8041